Latest news and press releases about Aytu BioPharma, Inc. (AYTU): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets.
Price
| Price | $1.97 |
| Market Cap | $21M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.58 |
| EV / EBITDA | -0.73 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -148.91% |
| Return on Invested Capital | -23.62% |
| Return on Assets | -30.49% |
| Gross Margin | 62.50% |
| Operating Margin | -26.79% |
| Net Margin | -60.17% |
Related companies: ADAP · ALUR · ANL · BFRI · EKSO · GOVX · NVNO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of AYTU: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks